Literature DB >> 23601055

Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems.

Daniel Fuster1, Judith I Tsui, Debbie M Cheng, Emily K Quinn, Kaku A Armah, David Nunes, Matthew S Freiberg, Jeffrey H Samet.   

Abstract

Both HIV and hepatitis C virus (HCV) cause chronic inflammation and alterations in serum inflammatory cytokines. The impact of inflammatory cytokines on liver fibrosis is not well understood. We studied the association between interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α and liver fibrosis in HIV-infected patients with current or past alcohol problems (CAGE ≥2 or physician investigator diagnosis). Liver fibrosis was estimated with FIB-4 (FIB-4 <1.45 defined the absence of liver fibrosis and FIB-4 >3.25 defined advanced fibrosis). Logistic regression was used to assess the association between cytokines and fibrosis, adjusting for age, sex, CD4, HIV RNA, current antiretroviral therapy, body mass index, and HCV. Secondary analyses explored whether the association between HCV and liver fibrosis was mediated by these cytokines. Participants (n=308) were all HIV-infected; 73% were male with a mean age of 42 years; half had detectable HCV-RNA, 60.7% had an absence of liver fibrosis, and 10.1% had advanced fibrosis. In models that adjusted for each cytokine separately, higher levels of IL-6 were significantly associated with an absence of fibrosis [adjusted OR (95% CI): 0.43 (0.19, 0.98), p=0.05] and were borderline significant for advanced fibrosis [adjusted OR (95% CI): 8.16 (0.96, 69.54), p=0.055]. In the final model, only higher levels of IL-6 remained significantly associated with advanced liver fibrosis [adjusted OR (95% CI): 11.78 (1.17, 118.19), p=0.036]. Adjustment for inflammatory cytokines attenuated the adjusted OR for the association between HCV and fibrosis in the case of IL-6 [for the absence of fibrosis from 0.32 (0.17, 0.57) p<0.01 to 0.47 (0.23, 0.96) p=0.04; and for advanced fibrosis from 7.22 (2.01, 25.96) p<0.01 to 6.62 (1.20, 36.62) p=0.03], suggesting IL-6 may be a partial mediator of the association between HCV and liver fibrosis. IL-6 was strongly and significantly associated with liver fibrosis in a cohort of HIV-infected patients with alcohol problems. IL-6 may be a useful predictive marker for liver fibrosis for HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23601055      PMCID: PMC3715787          DOI: 10.1089/AID.2012.0348

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  43 in total

1.  The use of the mini-mental state examination in recruitment for substance abuse research studies.

Authors:  Kristofer L Smith; Nicholas J Horton; Richard Saitz; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2005-10-26       Impact factor: 4.492

2.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Authors:  Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

3.  Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.

Authors:  Lidia Aranzabal; José L Casado; Javier Moya; Carmen Quereda; Sergio Diz; Ana Moreno; Leonor Moreno; Antonio Antela; Maria J Perez-Elias; Fernando Dronda; Ana Marín; Felix Hernandez-Ranz; Alberto Moreno; Santiago Moreno
Journal:  Clin Infect Dis       Date:  2005-01-21       Impact factor: 9.079

Review 4.  Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection.

Authors:  Anaïs Vallet-Pichard; Stanislas Pol
Journal:  J Hepatol       Date:  2005-11-21       Impact factor: 25.083

5.  Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity.

Authors:  Gyongyi Szabo; Costica Aloman; Stephen J Polyak; Steven A Weinman; Jack Wands; Sam Zakhari
Journal:  Alcohol Clin Exp Res       Date:  2006-04       Impact factor: 3.455

6.  Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression.

Authors:  Abdel-Rahman N Zekri; Mohammed S El-Din Ashour; Ahmed Hassan; Hanaa M Alam El-Din; Amal M R El-Shehaby; Maha A Abu-Shady
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

Review 7.  Liver fibrosis.

Authors:  Ramón Bataller; David A Brenner
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

8.  Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection.

Authors:  A Gramenzi; P Andreone; E Loggi; F G Foschi; C Cursaro; M Margotti; M Biselli; M Bernardi
Journal:  J Viral Hepat       Date:  2005-09       Impact factor: 3.728

9.  Viral factors associated with cytokine expression during HCV/HIV co-infection.

Authors:  Jason T Blackard; Minhee Kang; J Benjamin St Clair; Wenyu Lin; Yoshitaka Kamegaya; Kenneth E Sherman; Margaret James Koziel; Marion G Peters; Janet Andersen; Raymond T Chung
Journal:  J Interferon Cytokine Res       Date:  2007-04       Impact factor: 2.607

10.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

View more
  12 in total

1.  Factors Associated With Plasma IL-6 Levels During HIV Infection.

Authors:  Álvaro H Borges; Jemma L O'Connor; Andrew N Phillips; Frederikke F Rönsholt; Sarah Pett; Michael J Vjecha; Martyn A French; Jens D Lundgren
Journal:  J Infect Dis       Date:  2015-02-26       Impact factor: 5.226

2.  Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels.

Authors:  Shailja Shah; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael Plankey; Marion G Peters; Carl Grunfeld; Phyllis C Tien
Journal:  AIDS       Date:  2015-07-17       Impact factor: 4.177

3.  Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.

Authors:  Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re
Journal:  Clin Infect Dis       Date:  2014-02-25       Impact factor: 9.079

4.  Role of intestinal myofibroblasts in HIV-associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy.

Authors:  David M Asmuth; Irina V Pinchuk; Jian Wu; Gracie Vargas; Xiaoli Chen; Surinder Mann; Anthony Albanese; Zhong-Min Ma; Ramez Saroufeem; Gregory P Melcher; Paolo Troia-Cancio; Natalie J Torok; Christopher J Miller; Don W Powell
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

Review 5.  The significance of YKL-40 protein in liver fibrosis.

Authors:  Hui Tao; Jing-Jing Yang; Kai-Hu Shi; Cheng Huang; Lei Zhang; Xiong-Wen Lv; Jun Li
Journal:  Inflamm Res       Date:  2014-01-19       Impact factor: 4.575

6.  Monocyte subsets in schistosomiasis patients with periportal fibrosis.

Authors:  Jamille Souza Fernandes; Maria Ilma Araujo; Diego Mota Lopes; Robson da Paixão de Souza; Edgar M Carvalho; Luciana Santos Cardoso
Journal:  Mediators Inflamm       Date:  2014-03-13       Impact factor: 4.711

7.  D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events.

Authors:  Matthew S Freiberg; Ionut Bebu; Russell Tracy; Kaku So-Armah; Jason Okulicz; Anuradha Ganesan; Adam Armstrong; Thomas O'Bryan; David Rimland; Amy C Justice; Brian K Agan
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

Review 8.  Neuropilin-1: A feasible link between liver pathologies and COVID-19.

Authors:  Aitor Benedicto; Iñigo García-Kamiruaga; Beatriz Arteta
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

9.  Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study.

Authors:  Kaku A Armah; Emily K Quinn; Debbie M Cheng; Russell P Tracy; Jason V Baker; Jeffrey H Samet; Matthew S Freiberg
Journal:  BMC Infect Dis       Date:  2013-08-29       Impact factor: 3.090

10.  HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".

Authors:  Payal Kohli; Peter Ganz; Yifei Ma; Rebecca Scherzer; Sophia Hur; Bernard Weigel; Carl Grunfeld; Steven Deeks; Scott Wasserman; Rob Scott; Priscilla Y Hsue
Journal:  J Am Heart Assoc       Date:  2016-04-29       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.